Rheumatology key messagesTofacitinib 5 and 10 mg twice daily improved patient-reported outcomes *vs* placebo in RA patients.Adalimumab 40 mg every other week improved patient-reported outcomes *vs* placebo in RA patients.In RA patients, tofacitinib treatment improved patient-reported outcomes from month 3 to month 12.

Introduction
============

Pain, fatigue and poor physical functioning associated with RA affect health-related quality of life (HRQoL), resulting in a significant disease burden \[[@kev442-B1]\]. Additionally, the broad impact of RA frequently leads to sleep disturbances and difficulty performing everyday activities, including social and occupational roles \[[@kev442-B5], [@kev442-B6]\].

Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib 5 and 10 mg twice daily (BID) has been investigated in six phase 3 randomized controlled trials (RCTs) as monotherapy or in combination with non-biologic DMARDs, mostly MTX \[[@kev442-B7]\]. One of these phase 3 RCTs (ORAL Standard; A3921064; NCT00853385) included the tumor necrosis factor inhibitor (TNFi) adalimumab, administered in combination with background MTX, as an active control \[[@kev442-B7]\]. In addition to demonstrating clinically meaningful reductions in the signs and symptoms of RA, TNFis can significantly improve patient-reported outcomes (PROs) \[[@kev442-B13]\]. Therefore, it is of interest to examine whether tofacitinib 5 and 10 mg BID similarly affect PROs, in addition to the reported improvements in signs and symptoms of RA, physical function and structural preservation previously demonstrated in the clinical development program for tofacitinib \[[@kev442-B7]\]. Indeed, improvements in a number of PROs have been reported in tofacitinib phase 3 RCTs \[[@kev442-B14]\]. Here we report PROs from the tofacitinib ORAL Standard phase 3 RCT, which investigated the effects over 12 months of tofacitinib 5 and 10 mg BID, and adalimumab, in patients with moderate to severely active RA and inadequate responses to MTX.

Methods
=======

Full details of the randomized, double-blind ORAL Standard trial design have been reported previously \[[@kev442-B7]\]. Patients ⩾18 years old with active RA (defined by the ACR 1987 Revised Criteria \[[@kev442-B19]\]) were randomized to receive oral tofacitinib 5 or 10 mg BID, adalimumab 40 mg subcutaneous injection self-administered once every 2 weeks, or placebo (advanced to either tofacitinib 5 or 10 mg BID). All patients had received 7.5--25 mg of MTX weekly with sufficient residual disease activity to meet entry criteria. Key exclusion criteria included: current treatment with other synthetic/biologic anti-rheumatic agents; prior treatment with adalimumab; lack of response to prior TNFi treatment; and current active or inadequately treated infection with *Mycobacterium tuberculosis*. After the publication of the ORAL Standard primary manuscript \[[@kev442-B7]\], one of its study sites (nine patients randomized) was found to be non-compliant to study procedures, and those patients have been removed from the analyses presented here.

At month 3, patients receiving placebo without ⩾20% improvements in swollen and tender joint counts (defined as non-responders) were advanced blindly to tofacitinib 5 or 10 mg BID (dose was determined at initial randomization). At month 6, all remaining placebo patients were advanced to tofacitinib 5 or 10 mg BID. Non-responders who were initially randomized to tofacitinib or adalimumab continued with the same regimens for the trial duration.

The final protocol, amendments and informed consent documentation of the phase 3 study were approved by the Institutional Review Board and the Independent Ethics Committee of the investigational centers. All patients provided written, informed consent according to the Declaration of Helsinki (updated 2008). This analysis was included in the ethical approval.

Assessment of PROs
------------------

Mean change from baseline in HAQ-Disability Index (HAQ-DI) score at month 3 was a co-primary endpoint. HAQ-DI, Patient Global Assessment of Arthritis (PtGA) and Patient Assessment of Arthritis Pain (Pain; both evaluated using a 100 mm visual analog scale) were included as part of the ACR response criteria. With the exception of HAQ-DI, mean changes from baseline across all other PROs were pre-defined secondary endpoints and included: Short Form-36 (SF-36, Version 2, Acute), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and Medical Outcomes Study (MOS)-Sleep \[[@kev442-B20]\].

Minimum clinically important differences (MCIDs) have been defined in published studies using anchor-based methods \[[@kev442-B21]\] as follows: a 0.22-point decrease from baseline in HAQ-DI score \[[@kev442-B20]\]; 10 mm decreases from baseline in PtGA and Pain \[[@kev442-B22]\]; and increases from baseline of ⩾2.5 points in SF-36 Physical (PCS) and Mental Component Summary (MCS) scores; ⩾5 points in individual SF-36 domain scores \[[@kev442-B20]\]; and 4 points in FACIT-F score \[[@kev442-B20]\]. No MCID was available for MOS-Sleep \[[@kev442-B23]\].

HAQ-DI, PtGA, Pain and SF-36 were measured at all time points, including early discontinuation. FACIT-F and MOS-Sleep were assessed at baseline, months 1, 3, 6 and 12, or early discontinuation.

Statistical analysis
--------------------

Endpoints were expressed as changes from baseline and analyzed using a longitudinal mixed-effect repeated-measures model. This model was based on the full analysis set (all patients who received ⩾1 dose of study drug and ⩾1 post-baseline assessment). Treatment, week and treatment-by-week interaction were included as fixed effects, along with patients as a random effect. Estimates of mean changes for each treatment as well as mean differences from placebo were derived from the model as least squares means (LSMs), along with corresponding standard errors. The study was not designed to formally test non-inferiority of tofacitinib compared with adalimumab.

The percentage of patients reporting improvements ⩾MCID at month 3 was compared between active and placebo treatment groups (except for MOS-Sleep) in a post hoc analysis by forming a *Z*-score using the normal approximation to binomial rates. Statistical significance was declared at P ⩽ 0.05 based on two-sided tests, with no correction for multiple secondary comparisons. The Numbers Needed to Treat (NNTs) were calculated as the inverse of the following: rate of patients in the placebo group failing to report improvements ≥ MCID minus rate of patients on active treatment failing to report improvements ⩾ MCID (i.e. the estimated number of patients that must be treated to prevent one additional negative outcome).

SF-36 data were compared with a published data set reporting means and standard deviations of SF-36 scores by age group and gender, as well as normed values, from a US population of healthy individuals \[[@kev442-B24]\]. The reported means and standard deviations were used to inverse-transform the norming of these patients, and the values were re-weighted using weights from the age ranges and genders observed in the present study. The results from the current study (e.g. at baseline) could then be compared with the values from healthy individuals as a benchmark. SF-36 domain data are displayed using Spydergram^©^ plots, in which eight vertices (representing the eight SF-36 domains) radiate for the origin in a circular plot. Mean values are plotted on the vertices and connected by a line for each condition. The area is filled with colour for ease of review and comparison (e.g. with overlaid mean re-weighted values from healthy individuals). A larger area indicates higher HRQoL (on average) for patients.

Results
=======

Patients
--------

Randomized patients (n = 717, full analysis set) across treatment groups were predominantly female (range 75.0--85.3%) and white (67.3--74.0%), with mean disease duration ranging from 6.9 to 9.0 years \[[@kev442-B7]\]. Patient demographics and disease activity were similar across treatment groups \[[@kev442-B7]\]. In total, 556 (77.5%) patients completed the 12-month trial \[[@kev442-B7]\]; discontinuations were similar between tofacitinib and adalimumab treatment groups, including those due to adverse events \[[@kev442-B7]\].

Baseline values
---------------

At baseline, mean HAQ-DI scores ranged from 1.41 to 1.52, indicating impaired physical function; mean PtGA and Pain scores were 54.33--60.04 ([Table 1](#kev442-T1){ref-type="table"}). Large decrements in reported HRQoL were evident compared with an age- and gender-matched US normative population ([Fig. 1](#kev442-F1){ref-type="fig"}) as a benchmark; SF-36 PCS and MCS scores were approximately 2 and 1 standard deviations lower than the normative value of 50, respectively \[[@kev442-B24]\]. Baseline domain scores were lowest in Physical Functioning, Role Physical and Bodily Pain domains: 36.0--38.9 points below normative data. Next lowest were Social Functioning and Role Emotional domains (29.7--31.3 points lower), followed by General Health (28.9 points lower). F[ig]{.smallcaps}. 1Spydergram^©a^ representing mean overall SF-36 domain scores at month 3 (full analysis set, no imputation)All patients received background MTX. ^a^Study values were normed using population mean and standard deviations, see \[[@kev442-B24]\]. ^b^(**A**--**E**) report treatment group baselines (**A** using separate colours); (**F**) reports weighted combined baseline across all treatment groups. Placebo, n = 106 at baseline and n = 99 at month 3; tofacitinib 5 mg BID, n = 201 at baseline and n = 188 at month 3; tofacitinib 10 mg BID, n = 199 at baseline and n = 185 at month 3; adalimumab, n = 201 at baseline and n = 190 at month 3. BID: twice daily; BP: Bodily Pain; GH: General Health; MH: Mental Health; MTX: methotrexate; PF: Physical Functioning; Q2W: once every 2 weeks; RE: Role Emotional; RP: Role Physical; SC: subcutaneous; SF: Social Functioning; SF-36: Short Form-36; VT: Vitality. T[able]{.smallcaps} 1Baseline PRO measures (mean) and LSM changes from baseline at month 3PRO measureBaseline, mean (SD)LSM (SE) change from baseline to month 3[^a^](#kev442-TF1){ref-type="fn"}PlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDAdalimumab 40 mg Q2WPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDAdalimumab 40 mg Q2W+ MTX+ MTX+ MTX+ MTX+ MTX+ MTX+ MTX+ MTXn = 104^b^n = 198^b^n = 197^b^n = 199^b^n = 96n = 185n = 183n = 188HAQ-DI1.41 (0.68)1.50 (0.64)1.52 (0.63)1.50 (0.58)−0.24 (0.05)−0.54 (0.04)\*\*\*−0.61 (0.04)\*\*\*−0.50 (0.04)\*\*\*PtGA54.33 (21.42)60.04 (21.42)56.46 (23.85)57.06 (22.26)−7.27 (2.25)−23.79 (1.67)\*\*\*−26.38 (1.68)\*\*\*−21.47 (1.66)\*\*\*Pain55.03 (21.44)59.19 (21.09)58.85 (22.23)56.29 (21.97)−9.50 (2.19)−26.74 (1.63)\*\*\*−27.82 (1.64)\*\*\*−22.49 (1.62)\*\*\*FACIT-F30.38 (10.30)28.15 (10.49)28.64 (10.82)27.92 (10.12)1.57 (0.79)5.85 (0.59)^c,^\*\*\*6.88 (0.59)\*\*\*5.04 (0.58)\*\*MOS-Sleep41.34 (19.65)^d^43.12 (19.96)^e^42.29 (19.42)^e^43.19 (19.52)^f^−3.57 (1.43)^g^−7.31 (1.07)^h,^\*−8.43 (1.06)^i,^\*−4.49 (1.05)^j^SF-36    PCS33.07 (6.28)33.14 (7.74)32.70 (7.79)32.70 (6.80)3.17 (0.70)6.98 (0.52)^c,^\*\*\*7.81 (0.52)\*\*\*6.26 (0.52)^j,^\*\*    MCS43.25 (10.67)39.78 (11.69)40.16 (11.16)40.61 (11.69)1.77 (0.88)3.16 (0.66)^c^6.09 (0.66)\*\*\*3.38 (0.65)^j^Physical Functioning32.38 (9.44)32.06 (9.53)31.20 (9.47)31.70 (8.94)2.98 (0.83)6.24 (0.62)^c,^\*7.02 (0.62)\*\*\*4.99 (0.61)\*Role Physical34.55 (7.99)33.91 (9.09)33.60 (9.14)34.79 (8.73)2.90 (0.84)6.01 (0.62)\*7.15 (0.62)\*\*\*5.30 (0.62)\*Bodily Pain34.58 (6.60)33.46 (7.56)33.30 (7.41)33.08 (7.26)3.73 (0.84)8.18 (0.62)^c,^\*\*\*10.07 (0.62)\*\*\*7.96 (0.62)\*\*\*General Health36.33 (8.44)35.30 (8.90)35.80 (8.96)35.23 (7.99)2.12 (0.69)4.44 (0.51)\*6.38 (0.52)\*\*\*4.93 (0.51)^j,^\*\*Vitality42.61 (8.93)40.57 (9.24)40.74 (9.39)39.89 (9.57)2.21 (0.82)4.97 (0.61)\*7.21 (0.61)\*\*\*5.35 (0.60)\*Social Functioning39.44 (11.26)36.25 (10.79)36.23 (11.63)36.24 (11.56)3.46 (0.91)5.39 (0.68)7.98 (0.68)\*\*\*4.44 (0.67)Role Emotional37.30 (12.06)34.07 (12.52)34.17 (12.66)35.59 (12.10)2.10 (1.05)4.07 (0.78)6.90 (0.79)\*\*4.04 (0.78)Mental Health41.08 (10.61)39.00 (11.42)39.13 (11.22)39.67 (11.25)2.02 (0.87)3.36 (0.64)5.73 (0.65)\*\*3.83 (0.64)[^1]

Efficacy
--------

### HAQ-DI, PtGA and Pain

At month 3, treatment with both tofacitinib doses and adalimumab resulted in significant improvements *vs* placebo (P \< 0.0001) in HAQ-DI, PtGA and Pain ([Table 1](#kev442-T1){ref-type="table"}). LSM changes from baseline at month 3 were sustained to month 12 in these three treatment groups ([Fig. 2](#kev442-F2){ref-type="fig"}A--C). F[ig]{.smallcaps}. 2LSM (SE) change from baseline (full analysis set, longitudinal model)\*P ≤ 0.05, \*\*P \< 0.001 and \*\*\*P \< 0.0001 *vs* placebo + MTX. (**A**) Physical Functioning (HAQ-DI); (**B**) Patient Global Assessment of Arthritis; and (**C**) Patient Assessment of Arthritis Pain. Each individual graph has two separate analyses plotted. For baseline to month 6, patients who advanced at month 3 had their month 6 value set to missing for the purpose of statistically testing *vs* placebo. For post-month 6, all available patient data are included. BID: twice daily; HAQ-DI: Health Assessment Questionnaire-Disability Index; LSM: least squares mean; MTX: methotrexate; Pain: Patient Assessment of Arthritis Pain; PtGA: Patient Global Assessment of Arthritis; Q2W: once every 2 weeks; SC: subcutaneous; SE: standard error.

At month 3, significantly greater proportions of patients reported improvements ⩾MCID in HAQ-DI, PtGA and Pain *vs* placebo with both tofacitinib doses and adalimumab; the highest with tofacitinib 5 mg BID by PtGA (70.27%; P \< 0.0001 *vs* placebo), and with tofacitinib 10 mg BID by HAQ-DI (70.49%; P \< 0.001 *vs* placebo) and Pain (72.68%; P \< 0.0001 *vs* placebo) ([Table 2](#kev442-T2){ref-type="table"}). NNTs for these outcomes, which provide an estimate of the number of patients that must be treated to prevent one additional negative outcome, ranged from 2.9 to 5.5 for tofacitinib 5 mg BID, 3.0 to 4.6 for tofacitinib 10 mg BID and 3.5 to 6.3 for adalimumab ([Table 2](#kev442-T2){ref-type="table"}). T[able]{.smallcaps} 2Percentage of patients reporting improvements ≥MCID at month 3 and NNT to achieve ≥ MCID response (full analysis set, no imputation)PRO measurePlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDAdalimumab 40 mg Q2W(*MCID*)+ MTX+ MTX+ MTX+ MTXn = 96n = 185n = 183n = 188HAQ-DI48.96    % patients reporting ≥MCID (−0.22)67.03\*70.49\*\*64.89\*    NNT5.54.66.3PtGA35.42    % patients reporting ≥MCID (−10)70.27\*\*\*67.76\*\*\*64.36\*\*\*    NNT2.93.13.5Pain39.58    % patients reporting ≥MCID (−10)69.19\*\*\*72.68\*\*\*64.36\*\*\*    NNT3.43.04.0FACIT-F35.42    % patients reporting ≥MCID (4)55.98\*\*[^a^](#kev442-TF2){ref-type="fn"}59.56\*\*\*53.19\*    NNT4.94.15.6SF-36    PCS score51.04        % patients reporting ≥MCID (2.5)67.93\*[^a^](#kev442-TF2){ref-type="fn"}73.22\*\*66.31\*^b^        NNT5.94.56.5    MCS score42.71        % patients reporting ≥MCID (2.5)50.00[^a^](#kev442-TF2){ref-type="fn"}62.84\*51.87^b^        NNT13.75.010.9    Physical Functioning30.21        % patients reporting ≥MCID (5.0)48.37\*[^a^](#kev442-TF2){ref-type="fn"}53.55\*\*\*44.15\*        NNT5.54.37.2    Role Physical25.00        % patients reporting ≥MCID (5.0)47.03\*\*53.55\*\*\*41.49\*        NNT4.53.56.1    Bodily Pain32.29        % patients reporting ≥MCID (5.0)54.35\*\*[^a^](#kev442-TF2){ref-type="fn"}60.11\*\*\*53.19\*\*        NNT4.53.64.8    General Health20.83        % patients reporting ≥MCID (5.0)37.30\*50.27\*\*\*39.04\*\*        NNT6.13.45.5    Vitality29.17        % patients reporting ≥MCID (5.0)51.89\*\*59.02\*\*\*54.26\*\*\*        NNT4.43.44.0    Social Functioning        % patients reporting ≥MCID (5.0)50.0058.3863.93\*55.85        NNT11.97.217.1    Role Emotional29.17        % patients reporting ≥MCID (5.0)40.5447.54\*40.43        NNT8.85.48.9    Mental Health35.42        % patients reporting ≥MCID (5.0)43.7850.82\*46.28        NNT12.06.59.2[^2]

### HRQoL by SF-36

As can be seen in [Fig. 1](#kev442-F1){ref-type="fig"}, improvements from baseline to month 3 were generally observed across SF-36 domains with active treatment ([Fig. 1](#kev442-F1){ref-type="fig"}B--E). Scores at month 3 were highest with tofacitinib 10 mg BID and lowest with placebo ([Fig. 1](#kev442-F1){ref-type="fig"}F). At month 3, patients receiving tofacitinib 10 mg BID reported statistically significant LSM changes from baseline *vs* placebo in both PCS and MCS scores (both P \< 0.0001) ([Table 1](#kev442-T1){ref-type="table"}), whereas those receiving tofacitinib 5 mg BID and adalimumab reported statistically significant LSM changes in PCS (P \< 0.0001 and P \< 0.001 *vs* placebo for tofacitinib 5 mg BID and adalimumab, respectively), but not MCS scores. Statistically significant LSM changes from baseline *vs* placebo in PCS scores were observed as early as month 1 across all active treatment groups, and improvements in PCS and MCS scores were sustained to month 12 ([Fig. 3](#kev442-F3){ref-type="fig"}). With the exception of month 9, patients receiving tofacitinib 10 mg BID reported the largest LSM changes in PCS scores, followed by those receiving tofacitinib 5 mg BID. Patients receiving tofacitinib 10 mg BID reported improvements in MCS scores to month 3, which stabilised and numerically exceeded both the tofacitinib 5 mg BID and adalimumab treatment groups through month 12 ([Fig. 3](#kev442-F3){ref-type="fig"}). Numerical improvements in MCS scores were observed with tofacitinib 5 mg BID and adalimumab by month 1; further improvements with tofacitinib 5 mg BID, and to a lesser extent adalimumab, were observed during months 3--6, with statistically significant LSM changes from baseline *vs* placebo observed at month 6 with tofacitinib 5 mg BID and adalimumab ([Fig. 3](#kev442-F3){ref-type="fig"}). The highest percentages of patients reporting improvements ⩾MCID in PCS and MCS scores with the lowest NNTs (with lower values reflecting better efficacy) were reported in patients receiving tofacitinib 10 mg BID; NNTs and proportions reporting improvements ⩾MCID were similar among patients receiving tofacitinib 5 mg BID and adalimumab ([Table 2](#kev442-T2){ref-type="table"}). F[ig]{.smallcaps}. 3LSM (SE) change from baseline in HRQoL (SF-36) (full analysis set, longitudinal model)\*P ≤ 0.05, \*\*P \< 0.001 and \*\*\*P \< 0.0001 *vs* placebo + MTX. (**A**) Physical Component Summary score; (**B**) Mental Component Summary score. Each individual graph has two separate analyses plotted. For baseline to month 6, patients who advanced at month 3 had their month 6 value set to missing for the purpose of statistically testing *vs* placebo. For post-month 6, all available patient data are included. BID: twice daily; HRQoL: health-related quality of life; LSM: least squares mean; MCS: Mental Component Summary; MTX: methotrexate; PCS: Physical Component Summary; Q2W: once every 2 weeks; SC: subcutaneous; SE: standard error; SF-36: Short Form-36.

At month 3, reported improvements from baseline in all eight SF-36 domains were greatest with tofacitinib 10 mg BID *vs* placebo (P \< 0.05; [Table 1](#kev442-T1){ref-type="table"}), and significantly more patients reported improvements ⩾MCID ([Table 2](#kev442-T2){ref-type="table"}). In the tofacitinib 5 mg BID and adalimumab treatment groups, LSM changes from baseline at month 3 were similar and statistically significant *vs* placebo across five domains, excluding Social Functioning, Role Emotional and Mental Health ([Table 1](#kev442-T1){ref-type="table"}), with significantly more patients reporting improvements ⩾MCID *vs* placebo ([Table 2](#kev442-T2){ref-type="table"}). NNTs ranged from 4.4 to 12.0 with tofacitinib 5 mg BID, 3.4 to 7.2 with tofacitinib 10 mg BID and 4.0 to 17.1 with adalimumab.

### FACIT-F and MOS-Sleep

LSM changes from baseline at month 3 in FACIT-F and MOS-Sleep scores were statistically significant *vs* placebo with tofacitinib 5 and 10 mg BID; LSM changes in FACIT-F, but not MOS-Sleep scores, were significant *vs* placebo with adalimumab ([Table 1](#kev442-T1){ref-type="table"}). Improvements in fatigue and sleep scores were maintained through month 12 ([Fig. 4](#kev442-F4){ref-type="fig"}). Fluctuations observed in the placebo to 5 mg BID and placebo to 10 mg BID groups between months 1--3 and months 3--6 reflected improvement and stabilization post-month 6, when all patients received active treatment ([Fig. 4](#kev442-F4){ref-type="fig"}). More patients receiving tofacitinib 5 mg BID (55.98%; P \< 0.001 *vs* placebo), 10 mg BID (59.56%; P \< 0.0001 *vs* placebo) or adalimumab (53.19%; P \< 0.05 *vs* placebo) reported improvements ⩾MCID by FACIT-F; NNTs were 4.9, 4.1 and 5.6, respectively ([Table 2](#kev442-T2){ref-type="table"}). F[ig]{.smallcaps}. 4LSM (SE) change from baseline (full analysis set, longitudinal model)\*P ≤ 0.05, \*\*P \< 0.001 and \*\*\*P \< 0.0001 *vs* placebo + MTX. (**A**) Fatigue (FACIT-F); (**B**) sleep (MOS-Sleep). Each individual graph has two separate analyses plotted. For baseline to month 6, patients who advanced at month 3 had their month 6 value set to missing for the purpose of statistically testing *vs* placebo. For post-month 6, all available patient data are included. BID: twice daily; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue; LSM: least squares mean; MOS: Medical Outcomes Study; MTX: methotrexate; Q2W: once every 2 weeks; SC: subcutaneous; SE: standard error.

Discussion
==========

The ORAL Standard trial was the first phase 3 study of tofacitinib to include an active control, thereby allowing an estimation of the relative efficacy and safety of tofacitinib *vs* the TNFi adalimumab, each administered with MTX, in patients with inadequate responses to MTX. However, it must be noted that the study was not designed to formally test the non-inferiority of tofacitinib *vs* adalimumab.

In this RCT, treatment with tofacitinib 5 and 10 mg BID or adalimumab all resulted in statistically significant and clinically meaningful improvements *vs* placebo in PROs that approached maximal at month 3, with further smaller improvements until month 6. This pattern of improvement was generally consistent with the primary efficacy data \[[@kev442-B7]\].

Previous studies \[[@kev442-B13], [@kev442-B25], [@kev442-B26]\] have highlighted the importance of physical functioning, pain and fatigue to patients with active RA \[[@kev442-B27]\]. In the current trial, improvements in HAQ-DI, PtGA and Pain, observed as early as month 1 and sustained to month 12, were consistent with changes reported in HRQoL and fatigue. Significantly greater proportions of patients reported improvements ⩾MCID in these outcomes with both tofacitinib doses and adalimumab, the highest being with tofacitinib 10 mg BID. The low NNTs, which provide an estimate of the number of patients that must be treated to prevent one additional negative outcome, observed with both tofacitinib doses (⩽5) for HAQ-DI, PtGA and Pain reflect the value of treatment to patients.

SF-36 summary and domain scores indicated that there was substantial disease burden and diminished HRQoL at baseline in this trial population ([Fig. 1](#kev442-F1){ref-type="fig"}). Significant improvements in SF-36 PCS and MCS (tofacitinib 10 mg BID only) scores were observed with tofacitinib and adalimumab at month 3; improvements across five SF-36 domains were also observed with adalimumab and tofacitinib 5 mg BID and across all eight SF-36 domains with tofacitinib 10 mg BID. These results indicate that tofacitinib not only improves physical function, global assessments of disease activity, pain and fatigue, but also other aspects of HRQoL, particularly well-being and emotional health of patients with RA. Statistically significant and clinically meaningful improvements *vs* placebo in the SF-36 Vitality domain were observed across all active treatment groups, consistent with changes reported in FACIT-F scores, including the percentage of patients reporting improvements ⩾MCID.

RA can have a major negative psychological impact on patients; for example, it is associated with depression, which occurs in \>13% of patients \[[@kev442-B27]\]. In this study, numerical improvements in Mental Health and Role Emotional domains of SF-36 were observed with tofacitinib 5 mg BID and adalimumab, and greater improvements in these domains were observed with tofacitinib 10 mg BID, which were statistically significant *vs* placebo. These results are consistent with observed improvements in these parameters with TNFis (e.g. adalimumab) \[[@kev442-B13], [@kev442-B30]\].

TNFis are proven to be efficacious treatments in patients with inadequate responses to MTX \[[@kev442-B31]\]. Improvements in PROs observed with adalimumab are consistent with previously published data in these patient populations, where significant improvements in HAQ-DI, PtGA, Pain and FACIT-F have been reported for up to 24 weeks of treatment \[[@kev442-B13], [@kev442-B34]\], and in HAQ-DI and SF-36 domains for up to 1 and 2 years of treatment \[[@kev442-B13], [@kev442-B30]\].

Sleep disturbance in RA is linked to pain, mood and disease activity. In a comparison between patients with RA and those with non-inflammatory disorders, up to 42% of sleep disturbance could be attributed to RA \[[@kev442-B5]\]. Patients receiving tofacitinib 5 or 10 mg BID or adalimumab reported numerically better improvements *vs* placebo at month 3 in FACIT-F and MOS-Sleep endpoints, which were sustained to month 12.

In conclusion, in the ORAL Standard phase 3 RCT, patients with moderate to severely active RA and inadequate responses to MTX reported clinically meaningful improvements across a broad range of PROs with tofacitinib 5 or 10 mg BID as well as with adalimumab. Maximal treatment effects were generally evident at month 3. The greatest improvements were observed with tofacitinib 10 mg BID, which were significantly superior to placebo across PROs at month 3. Significant improvements were also observed with tofacitinib 5 mg BID and with adalimumab across the majority of endpoints, with generally similar effect sizes observed between tofacitinib 5 mg BID and adalimumab.
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[^1]: ^a^HAQ-DI at month 3, as previously reported, was a co-primary end point \[[@kev442-B7]\]. ^b^Number of patients with available baseline patient-reported outcome data. ^c^n = 184. ^d^n = 103. ^e^n = 196. ^f^n = 198. ^g^n = 95. ^h^n = 181. ^i^n = 182. ^j^n = 187. \*P \< 0.05, \*\*P \< 0.001 and \*\*\*P \< 0.0001 *vs* placebo + MTX. BID: twice daily; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI: Health Assessment Questionnaire-Disability Index; LSM: least squares mean; MCS: Mental Component Summary; MOS: Medical Outcomes Study; MTX: methotrexate; Pain: Patient Assessment of Arthritis Pain; PCS: Physical Component Summary; PRO: patient-reported outcome; PtGA: Patient Global Assessment of Arthritis; SD: standard deviation; SE: standard error; SF-36: Short-Form 36; Q2W: once every 2 weeks.

[^2]: ^a^n = 184. ^b^n = 187. \*P \< 0.05, \*\*P \< 0.001 and \*\*\*P \< 0.0001 *vs* placebo + MTX. BID: twice daily; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI: Health Assessment Questionnaire-Disability Index; MCID: minimum clinically important difference; MCS: Mental Component Summary; MTX: methotrexate; NNT: number needed to treat; Pain: Patient Assessment of Arthritis Pain; PCS: Physical Component Summary; PRO: patient-reported outcome; PtGA: Patient Global Assessment of Arthritis; SF-36: Short-Form 36; Q2W: once every 2 weeks.
